The top 10 therapies contributed 87% of the Indian pharma market.

According to data from the AIOCD:

• Sales of CNS (central nervous system) therapies rose the most at 12%.

• This was followed by cardiac and anti-infectives, which grew 11.5% and 10.3%, respectively.

• Gastrointestinal therapies rose 10%, while pain management gained 10.2%.

The moving annual total—or the 12-month rolling sales of overall pharma products—rose 6.8% in December, as compared with a growth of 7.7% a year earlier.

Faster Than Industry

Torrent Pharmaceuticals Ltd. reported the highest growth in December at 17.3%, followed by Sun Pharmaceutical Industries Ltd., which rose 17.1%. Cipla Ltd., Alkem Laboratories Ltd. and Indoco Remedies Ltd. reported growth of 15.9% each, followed by Eris Lifesciences Ltd., which gained 15.8%.

Glenmark Pharmaceuticals Ltd., Lupin Ltd., and Mankind Pharma Ltd. reported a growth of 14.2%, 13.4%, and 12%, respectively. FDC Ltd., Alembic Pharmaceuticals Ltd., and Zydus Lifesciences Ltd. grew 10.8%, 10.2%, and 10%, respectively.

Ipca Laboratories Ltd. reported a growth of 8.8%, while Abbott India Ltd. posted 8% growth, underperforming the market. Dr Reddy’s Laboratories Ltd. reported a growth of 7.6%, followed by GlaxoSmithKline Pharmaceuticals Ltd., which posted a growth of 7%.

Ajanta Pharma Ltd. and JB Chemicals and Pharmaceuticals Ltd. saw growth of 5.7% and 5%, respectively. Pfizer Ltd. reported a decline of 6.7%.